An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

about

Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance

P2860

Q58547123-543EE8DF-54A6-47A9-9D96-DC43F90018FC

P2860

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

Item

http://www.wikidata.org/entity/Q48165470

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@en

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@nl

type

Item

label

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@en

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@nl

prefLabel

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@en

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@nl

P1476

An oligoclonal antibody durabl ...... rd-generation EGFR inhibitors.

@en

P2093

Ashish Noronha

http://www.w3.org/2001/XMLSchema#string

Dan Adreka

http://www.w3.org/2001/XMLSchema#string

Dominick Ga Burton

http://www.w3.org/2001/XMLSchema#string

Emilie Bousquet

http://www.w3.org/2001/XMLSchema#string

Georg Mahlknecht

http://www.w3.org/2001/XMLSchema#string

Hilah Gal

http://www.w3.org/2001/XMLSchema#string

Ilaria Marrocco

http://www.w3.org/2001/XMLSchema#string

Lee Roth

http://www.w3.org/2001/XMLSchema#string

Luigi Mazzeo

http://www.w3.org/2001/XMLSchema#string

Maicol Mancini

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

P304

294-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201708076

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29212784

http://www.w3.org/2001/XMLSchema#string

P932

5801506

http://www.w3.org/2001/XMLSchema#string

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

about

P2860

P2860

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932